You are viewing an incomplete version of our website. Please click to reload the website as full version.

Browse our anti-TNFSF12 (TNFSF12) Antibodies

Full name:
anti-Tumor Necrosis Factor (Ligand) Superfamily, Member 12 Antibodies (TNFSF12)
On are 128 Tumor Necrosis Factor (Ligand) Superfamily, Member 12 (TNFSF12) Antibodies from 24 different suppliers available. Additionally we are shipping TNFSF12 Kits (31) and TNFSF12 Proteins (30) and many more products for this protein. A total of 198 TNFSF12 products are currently listed.
Apo3l, Dr3l, Dr3lg, Tweak
list all antibodies Gene Name GeneID UniProt
TNFSF12 8742 O43508
TNFSF12 21944 O54907
TNFSF12 360548  

Show all species

Show all synonyms

Most Popular Reactivities for anti-TNFSF12 (TNFSF12) Antibodies

Select your species and application

anti-Human TNFSF12 Antibodies:

anti-Mouse (Murine) TNFSF12 Antibodies:

anti-Rat (Rattus) TNFSF12 Antibodies:

All available anti-TNFSF12 Antibodies

Go to our pre-filtered search.

Top referenced anti-TNFSF12 Antibodies

  1. Human Polyclonal TNFSF12 Primary Antibody for EIA, IHC (p) - ABIN501094 : Lynch, Wang, Lund, Chen, Leal, Wiley: TWEAK induces angiogenesis and proliferation of endothelial cells. in The Journal of biological chemistry 1999 (PubMed)
    Show all 5 references for ABIN501094

  2. Dog (Canine) Polyclonal TNFSF12 Primary Antibody for WB - ABIN2774826 : Park, Chung, Jung, Park, Lee: Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. in Scandinavian journal of rheumatology 2008 (PubMed)

  3. Horse (Equine) Polyclonal TNFSF12 Primary Antibody for WB - ABIN2792305 : Jin, Nakao, Nakayama, Yamaguchi, Kojima, Nakano, Tsuboi, Okumura, Yagita, Ogawa: Induction of RANTES by TWEAK/Fn14 interaction in human keratinocytes. in The Journal of investigative dermatology 2004 (PubMed)

More Antibodies against TNFSF12 Interaction Partners

Human Tumor Necrosis Factor (Ligand) Superfamily, Member 12 (TNFSF12) interaction partners

  1. The result of transwell assay revealed that TWEAK promoted LX-2 migration. Subsequently, our data testified that the expression and activity of MMP9 (show MMP9 Antibodies) was induced by TWEAK in LX-2 cells, which enhanced the migration. Furthermore, our findings showed that TWEAK upregulated the phosphorylation of IkappaBalpha (show NFKBIA Antibodies) and p65 (show GORASP1 Antibodies) protein to increase MMP9 (show MMP9 Antibodies) expression in LX-2 cells.

  2. In this review article, we summarize studies indicating that (i) Fn14 (show TNFRSF12A Antibodies) gene expression is low in normal brain tissue but is upregulated in advanced brain cancers and, in particular, in GB tumors ; TWEAK: Fn14 (show TNFRSF12A Antibodies) engagement as well as Fn14 (show TNFRSF12A Antibodies) overexpression can stimulate glioma cell migration, invasion and resistance to chemotherapeutic agents in vitro.

  3. Findings suggest that TWEAK may contribute to chronic renal changes and renal fibrosis by activating TGF-beta1 (show TGFB1 Antibodies) signaling pathway, and phosphorylation of Smad2 (show SMAD2 Antibodies) and p38 MAPK (show MAPK14 Antibodies) proteins was also involved in this signaling pathway.

  4. The reduced levels of sTWEAK with progression of Hashimoto's Thyroiditis and the significant correlation between the sTWEAK levels and anti-TPO (show THPO Antibodies) found in this study suggest that sTWEAK plays an active role in chronic inflammation in the pathogenesis of Hashimoto's Thyroiditis and in the progression of autoimmunity.

  5. Serum TWEAK might be a serologic biomarker candidate that reflects disease activity and renal involvement in patients with SLE

  6. TWEAK/Fn14 (show TNFRSF12A Antibodies) activation induces keratinocyte proliferation under psoriatic inflammation

  7. Heart failure with reduced ejection fraction (HF-REF (show THOC4 Antibodies)) patients present increased sTWEAK and sCD163 (show CD163 Antibodies) levels as well as sTWEAK/sCD163 (show CD163 Antibodies) ratio when compared to healthy subjects, however CHF itself appears to be associated with down-regulation of sTWEAK.

  8. The results demonstrated that vitreous fluid from patients with PDR had higher levels of TWEAK and Fn14 than that from T2DM patients without PDR, thus suggesting an important regulatory role of TWEAK/Fn14 signaling in the pathogenesis of PDR.

  9. The main determinant of nitroglycerin-mediated dilation was sTWEAK. In addition, decreased nitroglycerin-mediated dilation was associated with higher systolic blood pressure and pulse pressure. The main determinant of FMD (show FLNA Antibodies) was Kt/V. Increased flow-mediated dilation was associated with better dialysis efficiency and high total cholesterol and LDL-cholesterol.

  10. TWEAK levels are slightly elevated in CSF (show CSF2 Antibodies) in systemic lupus erythematosus patients compared with non-autoimmune controls, irrespective of the presence of neuropsychiatric disease manifestations. TWEAK levels in serum and CSF (show CSF2 Antibodies) do not seem to be a useful biomarker of CNS involvement in SLE.

Mouse (Murine) Tumor Necrosis Factor (Ligand) Superfamily, Member 12 (TNFSF12) interaction partners

  1. Findings suggest that TWEAK may contribute to chronic renal changes and renal fibrosis by activating TGF-beta1 (show TGFB1 Antibodies) signaling pathway, and phosphorylation of Smad2 (show SMAD2 Antibodies) and p38 MAPK (show MAPK14 Antibodies) proteins was also involved in this signaling pathway.

  2. TWEAK/Fn14 (show TNFRSF12A Antibodies) signaling represses PGC-1alpha (show PPARGC1A Antibodies) expression during acute kidney injury through activation of canonical NF-kappaB (show NFKB1 Antibodies) pathways and epigenetic mechanisms including histone deacetylation on NF-kappaB (show NFKB1 Antibodies)-binding sites.

  3. These findings suggest that TWEAK signaling might be an aspect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine -mediated neuropathology and be involved in the overall neurodegenerative pathology of Parkinson's disease

  4. results revealed that TWEAK and Fn14 (show TNFRSF12A Antibodies) are expressed by uterine natural killer cells in pregnant mice

  5. studies show that signaling via TWEAK is deleterious to muscle in RNA toxicity and support the demonstrated utility of anti-TWEAK therapeutics.

  6. During ischaemia, soluble CD163 (show CD163 Antibodies) functions as a decoy receptor for TWEAK, to regulate TWEAK-induced activation of canonical nuclear factor-kappaB and Notch (show NOTCH1 Antibodies) signalling necessary for myogenic progenitor cell proliferation.

  7. TWEAK/Fn14 (show TNFRSF12A Antibodies) interactions play an important role in the pathogenesis of neuropsychiatric lupus by increasing the accumulation of inflammatory cells in the choroid plexus, disrupting blood brain barrier integrity, and increasing neuronal damage

  8. Tweak regulates astrogliosis, microgliosis and skeletal muscle atrophy in a mouse model of amyotrophic lateral sclerosis

  9. The results demonstrated that the expression levels of TWEAK and p-p38 MAPK (show MAPK14 Antibodies) increased in the periprosthetic interface membrane tissues and the RAW cells stimulated with Ti particles

  10. TWEAK/Fn14 (show TNFRSF12A Antibodies) signaling is strongly implicated in the pathogenesis of the cutaneous manifestations in the MRL/lpr (show FAS Antibodies) model of spontaneous lupus in mice.

TNFSF12 Antigen Profile

Antigen Summary

The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein is a ligand for the FN14/TWEAKR receptor. This cytokine has overlapping signaling functions with TNF, but displays a much wider tissue distribution. This cytokine, which exists in both membrane-bound and secreted forms, can induce apoptosis via multiple pathways of cell death in a cell type-specific manner. This cytokine is also found to promote proliferation and migration of endothelial cells, and thus acts as a regulator of angiogenesis. Alternative splicing results in multiple transcript variants. Some transcripts skip the last exon of this gene and continue into the second exon of the neighboring TNFSF13 gene\; such read-through transcripts are contained in GeneID 407977, TNFSF12-TNFSF13.

Alternative names and synonyms associated with TNFSF12

  • tumor necrosis factor (ligand) superfamily, member 12 (TNFSF12) antibody
  • tumor necrosis factor (ligand) superfamily, member 12 (Tnfsf12) antibody
  • tumor necrosis factor ligand superfamily member 12 (Tnfsf12) antibody
  • Apo3l antibody
  • Dr3l antibody
  • Dr3lg antibody
  • Tweak antibody

Protein level used designations for TNFSF12

APO3 ligand , APO3/DR3 ligand , TNF-related WEAK inducer of apoptosis , tumor necrosis factor ligand superfamily member 12 , tumor necrosis factor superfamily member 12 , TNF-related weak inducer of apoptosis

8742 Homo sapiens
100568280 Canis lupus familiaris
21944 Mus musculus
360548 Rattus norvegicus
Selected quality suppliers for anti-TNFSF12 (TNFSF12) Antibodies
Did you look for something else?